Drug Trial Radar · NCT07311148
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 40 Years and Older
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
840
Planned (sponsor's estimate)
Start
Oct 23, 2025
Primary completion
Jan 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Guangzhou Patronus Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase 2 study in China will evaluate the immunogenicity and safety of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
Conditions
- Herpes Zoster (HZ)
- Shingles
- VZV
- Recombinant Zoster Vaccine
Interventions
Low dose antigen and low dose adjuvant of LYB004Biological
0.5 mL per dose, containing 25 μg VZV-gEM adjuvanted with A01C.
Low dose antigen and high dose adjuvant of LYB004Biological
0.5 mL per dose, containing 25 μg VZV-gEM adjuvanted with A01B.
High dose antigen and low dose adjuvant of LYB004Biological
0.5 mL per dose, containing 50 μg VZV-gEM adjuvanted with A01C.
High dose antigen and high dose adjuvant of LYB004Biological
0.5 mL per dose, containing 50 μg VZV-gEM adjuvanted with A01B.
PlaceboBiological
0.5 mL per dose, without antigen and adjuvant.
Positive controlBiological
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The geometric mean concentration (GMC) of anti-glycoprotein E (gE) antibodyTime frame: 30 days after second vaccination
- The geometric mean titer (GMT) of anti-VZV antibodyTime frame: 30 days after second vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hengnan County Center for Disease Control and Prevention
Hengyang, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.